Stockscreener 앱 받기
2.671
1.52%
0.031
전일 마감가:
$2.64
열려 있는:
$2.69
하루 거래량:
659.03K
Relative Volume:
0.41
시가총액:
$190.75M
수익:
-
순이익/손실:
$-192.96M
주가수익비율:
-0.8094
EPS:
-3.3
순현금흐름:
$-167.04M
1주 성능:
+3.88%
1개월 성능:
-2.19%
6개월 성능:
+65.43%
1년 성능:
+37.44%
1일 변동 폭
$2.54
$2.725
1주일 범위
$2.36
$2.88
52주 변동 폭
$0.783
$3.39
Ventyx Biosciences Inc Stock (VTYX) Company Profile
명칭
Ventyx Biosciences Inc
전화
(858) 945-2393
주소
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
VTYX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTYX
Ventyx Biosciences Inc
|
2.675 | 199.96M | 0 | -192.96M | -167.04M | -3.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.10 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.77 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.07 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
641.85 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
287.70 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-12 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-03-12 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-11-07 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-11-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-07 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-11-07 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-11-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-03-21 | 개시 | Wells Fargo | Overweight |
| 2022-12-19 | 개시 | Goldman | Buy |
| 2022-11-17 | 개시 | Morgan Stanley | Overweight |
| 2022-09-07 | 개시 | Stifel | Buy |
| 2022-09-01 | 개시 | H.C. Wainwright | Buy |
| 2022-05-09 | 개시 | Credit Suisse | Outperform |
| 2022-03-31 | 개시 | Canaccord Genuity | Buy |
| 2022-02-01 | 개시 | Oppenheimer | Outperform |
| 2021-11-15 | 개시 | Jefferies | Buy |
| 2021-11-15 | 개시 | Piper Sandler | Overweight |
모두보기
Ventyx Biosciences Inc 주식(VTYX)의 최신 뉴스
Tools to monitor Ventyx Biosciences Inc. recovery probabilityFree Stable Entry High Return Opportunities - Newser
Can Ventyx Biosciences Inc Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com
Smart tools for monitoring Ventyx Biosciences Inc.’s price actionReversal Signal Prediction Based on Volume - Newser
Detecting support and resistance levels for Ventyx Biosciences Inc.Weekly Outlook for Short Term Investors - Newser
What technical models suggest about Ventyx Biosciences Inc.’s comebackEntry Zone Watchlist With Momentum Focus - Newser
What MACD signals say about Ventyx Biosciences Inc.Free Weekly Watchlist of High Movers - Newser
Building trade automation scripts for Ventyx Biosciences Inc.Free Weekly Stock Opportunity Radar Scanner - Newser
What recovery options are there for Ventyx Biosciences Inc.Free Real Trader Watchlist of Hot Stocks - Newser
Ventyx Biosciences Inc. stock chart pattern explainedSwing Trade Watchlist with Entry Zones - Newser
Has Ventyx Biosciences Inc. Stock Ever Crashed Historical Volatility ReviewMomentum Screener with Buy and Sell Areas - Newser
A Quick Look at Today's Ratings for Ventyx Biosciences(VTYX.US), With a Forecast Between $9 to $21 - 富途牛牛
Ventyx Biosciences Earns Buy Rating: Analyst Cites Promising Developments - AInvest
Real time social sentiment graph for Ventyx Biosciences Inc.Chart Pattern Recognition for Profit Timing - Newser
Wall Street Zen Upgrades Ventyx Biosciences (NASDAQ:VTYX) to “Hold” - Defense World
Why Ventyx Biosciences Inc. stock attracts strong analyst attentionFree Oversold Recovery Opportunity Stocks - Newser
Is Ventyx Biosciences Inc. forming a bottoming baseChart Scanner for Swing Trade Timing - Newser
Applying big data sentiment scoring on Ventyx Biosciences Inc.Entry Zone Watchlist With Momentum Focus - Newser
Ventyx Biosciences shares surge 12.50% intraday after reporting better-than-expected Q2 earnings and positive biomarker data for VTX3232 in Parkinson's treatment. - AInvest
Ventyx Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Ventyx Biosciences Q2 2025 Earnings Beat Estimates, Cash Position at $209M - AInvest
Ventyx (VTYX) Q2 Net Loss Drops 16% - The Globe and Mail
Ventyx Biosciences Q2 GAAP EPS of -$0.38 Beats Expectations - AInvest
Ventyx Biosciences Q2 FY25 Revenue $5.4mln, Cash Balance $209mln. - AInvest
Ventyx Breakthrough: Phase 2 Parkinson's Drug Shows Promise, Plus Two Major Trial Results Expected in Q4 2025 - Stock Titan
What candlestick patterns are forming on Ventyx Biosciences Inc.Free Accurate Buy Point for Momentum Stocks - Newser
Ventyx Biosciences (VTYX) Projected to Post Earnings on Thursday - Defense World
Options Data Show Bullish Bias in Ventyx Biosciences Inc.Watchlist for Low Risk High Return Stocks Updated - beatles.ru
Will Ventyx Biosciences Inc. Bounce From 52 Week LowChart Driven High Reward Trading Setup Presented - beatles.ru
Published on: 2025-08-04 01:54:41 - Newser
How many analysts rate Ventyx Biosciences Inc. as a “Buy”Consistently high returns - Jammu Links News
What are the latest earnings results for Ventyx Biosciences Inc.Invest in high-yield stocks with confidence - Jammu Links News
What makes Ventyx Biosciences Inc. stock price move sharplyInvest smarter with advanced market data - Jammu Links News
H.C. Wainwright Maintains Hold on Ventyx Biosciences Despite Quarterly Loss - AInvest
Datadog Exceeds Forecasts, Raises Guidance Amid Robust Growth and High Valuation - AInvest
What are analysts’ price targets for Ventyx Biosciences Inc. in the next 12 monthsUnprecedented market success - Jammu Links News
What analysts say about Ventyx Biosciences Inc. stockAchieve breakthrough performance with smart picks - Jammu Links News
Is it time to cut losses on Ventyx Biosciences Inc.Early Entry Ideas with Momentum Potential - newser.com
Ventyx Biosciences Inc (VTYX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Ventyx Biosciences Inc 주식 (VTYX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Mohan Raju | CEO AND PRESIDENT |
Mar 28 '25 |
Option Exercise |
0.00 |
11,844 |
0 |
2,303,540 |
| Nuss John | CHIEF SCIENTIFIC OFFICER |
Mar 28 '25 |
Option Exercise |
0.00 |
4,531 |
0 |
469,113 |
| Nuss John | CHIEF SCIENTIFIC OFFICER |
Dec 27 '24 |
Sale |
2.36 |
21,119 |
49,841 |
464,582 |
0.81%
3.03%
자본화:
|
볼륨(24시간):